Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? - Wikidata - awgldk - TriplyDB

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

http://www.wikidata.org/entity/Q44060951

about

Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra Targeting molecular resistance in castration-resistant prostate cancer ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Abiraterone in the treatment of metastatic castration-resistant prostate cancer Current clinical challenges in prostate cancer Targeting the androgen receptor with steroid conjugates Chemotherapy and its evolving role in the management of advanced prostate cancer Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy Targeting the adaptive molecular landscape of castration-resistant prostate cancer Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.Androgen receptor splice variants determine taxane sensitivity in prostate cancer.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.Practical guide to the use of abiraterone in castration resistant prostate cancer.SEOM clinical guidelines for the treatment of metastatic prostate cancer Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents Androgen pathway resistance in prostate cancer and therapeutic implications Assessing the utility of cabazitaxel in mCRPC Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report.The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90 Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.Optimal therapy sequencing in metastatic castration-resistant prostate cancer.Metabolic and toxicological considerations of newly approved prostate cancer drugs.Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?

P2860

Q24289204-6EB27148-81BA-4F0A-A5DD-020C607C2DE5 Q26795445-ADC31FC8-9E2B-4C8E-9A59-31A9B60FA696 Q26796568-550FDEFE-0882-4634-8D30-1DEB517E3213 Q26796704-B9B94048-AE0F-47B0-A372-D5921D7FC889 Q26853635-F32419A2-9B17-4F7A-B4B1-517E32B5896C Q26866036-3B49CDC6-DE16-4CDB-9A61-3396FDE7E396 Q26995692-AF4920DA-6CE3-410E-868F-B2E6A4A8244B Q27008883-A5A36DC2-630E-47C4-83DF-AC1004B2E9F4 Q27011642-16A4DC8E-40C2-47C3-9E42-FC551330E26A Q27022715-BE6B5665-F22B-422F-BC6A-C67100DF269E Q27022821-90E6A184-55CE-43C1-BE2B-75EE84F566F8 Q30244818-322D9D93-0CAE-4E6C-9E6F-CA06C54CCE4B Q30248275-6642A3BF-B077-4CF3-8972-187A6A9EEF2D Q30577613-7F750998-0432-4004-BE1F-1DEE6BFF821E Q33621403-1C230CBC-6260-4990-988F-70CDBA08BFC4 Q33656820-415D8BD2-42A2-4869-B165-225F50E9B951 Q33775723-2044193D-67E2-4265-841F-AFA2CBA70539 Q33946666-DFA576A3-7545-429A-A02D-0B19DC9BB74F Q34070638-CE5B98CE-CE15-4349-B62A-0C0809DF5F64 Q34553405-A1740BB4-9D9F-4075-8541-372E6DAE76B8 Q35328550-C92B885D-CBBB-42EA-92B5-6D43C6F86B6B Q35358010-E1D3FACC-C2A6-4342-9AC7-00AA4C87E67D Q35602593-6CF714D9-0C7C-4A33-AF30-D85E34862A79 Q35879087-A6469B82-FEC8-4FF4-8101-AC280A119751 Q35932706-43DD253D-47CF-4E51-800C-42F7E8787D18 Q36243639-F55EDA60-C549-4760-915C-CFBBCC9EA0DD Q36410270-A788F0C1-048D-4C86-A5E3-9DFF16E9FB2D Q36414184-25E5A630-1092-4AFB-A2AE-D9E314D1743D Q36416370-5D417C2F-AE68-459E-B13A-AC8567FEC410 Q36823066-085B9CCE-B6A1-49B7-AC30-A03808587C52 Q36909750-F1D508E0-E013-45A2-A11D-AD7BDCF2FC74 Q36910062-CBE48F80-51C2-457C-BA66-78CEDFC81D12 Q36981441-380402D3-83FD-4DCB-B143-0618C47C1CEE Q37227713-B30B73CA-72C7-4860-8C6A-90A6556EB25A Q37735587-028F2115-520B-4410-9AD7-4B822AF2C764 Q38097373-416F6928-4748-4ACB-B5C3-B44F85C31BDC Q38098596-BECE386F-1F6F-4392-9DDB-A3F93EA2B522 Q38181005-18970245-B217-434C-8509-05840D25344A Q38183819-E8AEEBDE-B115-4F53-9422-0B17D9F5CC8E Q38195921-6B7CFC66-5A69-472E-9175-28A82032BBAE

P2860

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

http://www.wikidata.org/entity/Q44060951

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Antitumour activity of docetax ...... evidence for cross-resistance?

@en

Antitumour activity of docetax ...... evidence for cross-resistance?

@nl

type

label

Antitumour activity of docetax ...... evidence for cross-resistance?

@en

Antitumour activity of docetax ...... evidence for cross-resistance?

@nl

prefLabel

Antitumour activity of docetax ...... evidence for cross-resistance?

@en

Antitumour activity of docetax ...... evidence for cross-resistance?

@nl

P1433

Q44060951-49485197-E767-4EC2-8FDA-CD1497B76520

P1476

Q44060951-695C2AA7-37D1-4E0A-A3ED-AF0138F5D7F0

P2093

Q44060951-14B42F01-86B0-4A48-8BFC-6F756B8EAFBF

Q44060951-19F134C3-324C-4B1C-A101-23AEAA0C26A8

Q44060951-3C60D446-EE3D-48A1-AE9F-2D6F9E996D9F

Q44060951-4392D9E7-D87C-4E8F-9704-2F3AEFECE1EC

Q44060951-7C5E6B85-7B71-4D12-B858-8EEF0B117E04

Q44060951-9E32BCA3-6A90-49CA-BAB4-BBA5CF0A1699

Q44060951-A42404A8-CEEE-4C84-856C-2711ABDCDF4F

Q44060951-A650A646-F941-43E7-9F23-DF4F75385591

Q44060951-B0EACCE9-A75A-4847-90B8-54300F783E69

Q44060951-B4007CA9-0403-444E-AA6F-89D5E27181C8

P304

Q44060951-CE2AABB2-D7CD-4F12-A8B1-414BD0694585

P31

Q44060951-CA418A15-B046-4C64-82BC-23EDE54E4A74

P356

Q44060951-2B54BCFE-4265-44B9-A057-8F5A4FAC2E79

P433

Q44060951-96C9A3D9-E54C-4C46-B822-FBDE47358DFE

P478

Q44060951-CC3F77B4-7AD5-47FC-AE92-954BF773E733

P50

Q44060951-3A32725A-F25D-46AD-8813-523941B8211C

Q44060951-94DE9E86-E497-4DB8-8330-F4A52F47CC3C

P577

Q44060951-EC3C087C-6F77-4727-B2F8-5DDC5052B902

P5875

Q44060951-42C8A2D4-7E11-4430-9568-7DAA942949DA

P698

Q44060951-723F25DC-72C0-45AC-9D77-7C89B6C7053C

P356

P1433

Annals of Oncology

P1476

Antitumour activity of docetax ...... evidence for cross-resistance?

@en

P2093

A H M Reid

http://www.w3.org/2001/XMLSchema#string

A Mulick Cassidy

http://www.w3.org/2001/XMLSchema#string

A Sarvadikar

http://www.w3.org/2001/XMLSchema#string

A Zivi

http://www.w3.org/2001/XMLSchema#string

B Baikady

http://www.w3.org/2001/XMLSchema#string

C Pezaro

http://www.w3.org/2001/XMLSchema#string

D Bianchini

http://www.w3.org/2001/XMLSchema#string

D Olmos

http://www.w3.org/2001/XMLSchema#string

E Sheridan

http://www.w3.org/2001/XMLSchema#string

E Thompson

http://www.w3.org/2001/XMLSchema#string

P304

2943-2947

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDS119

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Gerhardt Attard

Shahneen K Sandhu

P577

2012-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228442656

http://www.w3.org/2001/XMLSchema#string

P698

22771826

http://www.w3.org/2001/XMLSchema#string